Twist Bioscience Corp
NASDAQ:TWST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth $-23.91 (142% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -45.4 | $56.7 |
0%
|
| Industry Average | 19.1 | $-23.91 |
-142%
|
| Country Average | 22.9 | $-28.58 |
-150%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Twist Bioscience Corp
NASDAQ:TWST
|
3.5B USD | -45.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Twist Bioscience Corp
Glance View
In the bustling world of biotechnology, Twist Bioscience Corp. has emerged as a trailblazer with its innovative approach to DNA synthesis technology. Founded on the premise of leveraging the power of synthetic DNA, Twist has unraveled the potential of precision engineering in genetics. The company operates with a unique silicon-based DNA synthesis platform, which allows for the rapid and cost-effective production of high-quality DNA. This cutting-edge technology facilitates advancements in various domains such as drug development, agricultural biology, and data storage. By addressing the ever-growing demand for synthesized DNA across these sectors, Twist positions itself at the intersection of technology and life sciences, offering a robust solution that fuels the DNA-driven innovations of tomorrow. At its core, Twist Bioscience generates revenue by providing its customers with a streamlined supply of custom DNA products, catering to researchers and businesses that require precise genetic sequences with high fidelity. This includes synthetic genes, oligonucleotide pools, and libraries used for CRISPR screening and other applications. The company has strategically diversified its offerings to include specialized DNA libraries and biopharmaceutical solutions, further extending its reach into therapeutic discovery and development. By aligning its business model with the needs of its clients, Twist ensures consistent growth by capitalizing on the expanding markets of biotechnology and synthetic biology, turning its pioneering technological capabilities into a profitable enterprise.